Aspire Biopharma Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Aspire Biopharma Holdings, Inc. carries a market capitalization of 694,539.00, placing it among publicly traded companies globally.
| Market Cap | 694,539.00 |
| Enterprise Value | N/A |
Share Statistics
Aspire Biopharma Holdings, Inc. currently has 167,470.00 shares outstanding.
| Shares Outstanding | 167,470.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.38, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 2.38 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.02 |
| P/FCF Ratio | -0.01 |
| P/OCF Ratio | -0.01 |
Financial Position
Aspire Biopharma Holdings, Inc. maintains a current ratio of 2.26, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.26 |
| Quick Ratio | 1.86 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -0.55 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -259.01 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.16 |
Stock Price Statistics
Aspire Biopharma Holdings, Inc.'s stock has declined approximately -98.69358% over the past 52 weeks. The 50-day moving average sits at 2.21, while the 200-day moving average is 6.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.69358% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 6.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aspire Biopharma Holdings, Inc. generated 34,555.00 in revenue and converted that into -11.76M in net income, yielding earnings per share of -147.60. EBITDA reached -5.44M, while operating income came in at -5.44M.
| Revenue | 34,555.00 |
| Gross Profit | 5,634.00 |
| Operating Income | -5.44M |
| Pretax Income | -11.76M |
| Net Income | -11.76M |
| EBITDA | -5.44M |
| EBIT | -5.44M |
| Earnings Per Share (EPS) | -147.60 |
Balance Sheet
Total book value stands at -30.48M, with working capital of 3.96M providing operational flexibility.
| Cash & Cash Equivalents | 5.86M |
| Total Debt | N/A |
| Net Debt | -4.36M |
| Equity (Book Value) | -30.48M |
| Book Value Per Share | -382.50 |
| Working Capital | 3.96M |
Cash Flow
Aspire Biopharma Holdings, Inc. produced -6.21M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.21M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.21M |
| FCF Per Share | -77.93 |
Margins
Aspire Biopharma Holdings, Inc. operates with a gross margin of 16.30, reflecting its pricing power and cost economics. The operating margin of -15,745.85 and net profit margin of -34,039.68 provide insight into operational efficiency.
| Gross Margin | 16.30 |
| Operating Margin | -15,745.85 |
| Pretax Margin | -34,039.68 |
| Profit Margin | -34,039.68 |
| EBITDA Margin | -15,745.85 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -13,061.65 |
| FCF Yield | -7,566.41 |
Stock Splits
Aspire Biopharma Holdings, Inc.'s most recent stock split took place on May 11, 2026 with a 30:1 split ratio.
| Last Split Date | 5/11/2026 |
| Split Ratio | 30:1 |
Scores
Aspire Biopharma Holdings, Inc. posts an Altman Z-Score of -7.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.83 |